Category: Uncategorized

Posted on

Corbus Pharmaceuticals to Present at the 2025 RBC Capital Markets Global Healthcare Conference

Norwood, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Corbus Pharmaceuticals Holdings, Inc. (NASDAQ: CRBP) (“Corbus” or the “Company”), today announced that Yuval Cohen, Ph.D., Chief Executive Officer of Corbus, will participate in a fireside chat and one-on-one investor meetings at the 2025 RBC Capital Markets Global Healthcare Conference, to be held May 20-21, 2025 in New York, NY.

2025 RBC Capital Markets Global Healthcare Conference

Format: Fireside chat and one-on-one investor meetings
Date: May 21, 2025
Time: 8:30 a.m. ET
Webcast: Click here

About Corbus

Corbus Pharmaceuticals Holdings, Inc. is an oncology and obesity company with a diversified portfolio and is committed to helping people defeat serious illness by bringing innovative scientific approaches to well-understood biological pathways. Corbus’ pipeline includes CRB-701, a next-generation antibody drug conjugate that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGFβ expressed on cancer cells, and CRB-913, a highly peripherally restricted CB1 receptor inverse agonist for the treatment of obesity. Corbus is headquartered in Norwood, Massachusetts. For more information on Corbus, visit corbuspharma.com. Connect with us on X, LinkedIn and Facebook.

Forward-Looking Statements

This press release contains certain forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934 and Private Securities Litigation Reform Act, as amended, including those relating to the Company’s trial results, product development, clinical and regulatory timelines, including timing for completion of trials and presentation of data, market opportunity, competitive position, possible or assumed future results of operations, business strategies, potential growth opportunities and other statement that are predictive in nature. These forward-looking statements are based on current expectations, estimates, forecasts and projections about the industry and markets in which we operate and management’s current beliefs and assumptions.

These statements may be identified by the use of forward-looking expressions, including, but not limited to, “expect,” “anticipate,” “intend,” “plan,” “believe,” “estimate,” “potential,” “predict,” “project,” “should,” “would” and similar expressions and the negatives of those terms. These statements relate to future events or our financial performance and involve known and unknown risks, uncertainties, and other factors on our operations, clinical development plans and timelines, which may cause actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements. Such factors include those set forth in the Company’s filings with the Securities and Exchange Commission. Prospective investors are cautioned not to place undue reliance on such forward-looking statements, which speak only as of the date of this press release. The Company undertakes no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise.

All product names, logos, brands, and company names are trademarks or registered trademarks of their respective owners. Their use does not imply affiliation or endorsement by these companies.


INVESTOR CONTACT:

Sean Moran

Chief Financial Officer

Corbus Pharmaceuticals
[email protected]

Bruce Mackle

Managing Director

LifeSci Advisors, LLC
[email protected]



Posted on

PDS Biotech Announces Additional Details on Two Preclinical Universal Influenza Presentations at IMMUNOLOGY2025™ Annual Meeting

Infectimune® studies funded by and performed by investigators at the National Institute of Allergy and Infectious Diseases (NIAID)’s Center for Influenza Vaccine Research for High-Risk Populations (CIVR-HRP)

PRINCETON, N.J., May 08, 2025 (GLOBE NEWSWIRE) — PDS Biotechnology Corporation (Nasdaq: PDSB) (“PDS Biotech” or the “Company”), a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers and infectious diseases, today provided updates on preclinical immune response data with a novel, investigational Infectimune® based flu vaccine that were featured at the American Association of Immunologists’ IMMUNOLOGY2025™ Annual Meeting, which took place May 3-7, 2025, in Honolulu, Hawaii.

As previously announced, on Sunday, May 4, 2025, Andrea Sant, Ph.D., Professor of Microbiology and Immunology at the University of Rochester Medical Center, presented “How immune memory from influenza infection shapes protective immune responses to vaccination,” during the International Society of Influenza and Other Respiratory Viruses (ISIRIV) sponsored symposium. The discussion described how, in preclinical influenza studies, the use of Infectimune® resulted in the elicitation of a significantly greater frequency of highly multifunctional, influenza-specific CD4 T cells that produced multiple cytokines compared to current vaccine approaches and also exhibited cytotoxic (cell killing) characteristics. Infectimune® was uniquely able to promote CD4 T cells that targeted lung tissue in those with a history of influenza infection.

Separately, on Tuesday May 6, 2025, James D. Allen, Ph.D., Program Director/Research Associate, Florida Research and Innovation Center, Cleveland Clinic, presented preclinical data in a poster (#2219) titled, “H3 Hemagglutinin proteins optimized for 2018-2022 elicit protective antibodies across panels of modern influenza A (H3N2) viruses.” In preclinical ferret studies, Infectimune® based universal flu vaccines, comprised of PDS Biotech-licensed computationally optimized broadly reactive antigens (COBRAs), neutralized and protected against historical H3N2 influenza strains that occurred between 2014 and 2021, demonstrating excellent breadth of protective immune response against multiple strains of influenza.

“With increasing recent interest in universal vaccines as the next frontier in influenza vaccine development, we are pleased to see continued interest from leading experts in the potential of Infectimune® as a promising option,” said Frank Bedu-Addo, PhD, President and Chief Executive Officer of PDS Biotech. “This collaborative approach allows PDS Biotech to focus our resources on our immuno-oncology programs, particularly our VERSATILE-003 Phase 3 clinical trial evaluating Versamune® HPV in recurrent/metastatic HPV16-positive head and neck squamous carcinoma (“HNSCC”).”

About PDS Biotechnology

PDS Biotechnology is a late-stage immunotherapy company focused on transforming how the immune system targets and kills cancers. The Company has initiated a pivotal clinical trial to advance its lead program in advanced HPV16-positive head and neck squamous cell cancers. PDS Biotech’s lead investigational targeted immunotherapy Versamune® HPV is being developed in combination with a standard-of-care immune checkpoint inhibitor, and also in a triple combination including PDS01ADC, an IL-12 fused antibody drug conjugate (ADC), and a standard-of-care immune checkpoint inhibitor.

For more information, please visit www.pdsbiotech.com

Forward Looking Statements

This communication contains forward-looking statements (including within the meaning of Section 21E of the United States Securities Exchange Act of 1934, as amended, and Section 27A of the United States Securities Act of 1933, as amended) concerning PDS Biotechnology Corporation (the “Company”) and other matters. These statements may discuss goals, intentions and expectations as to future plans, trends, events, results of operations or financial condition, or otherwise, based on current beliefs of the Company’s management, as well as assumptions made by, and information currently available to, management. Forward-looking statements generally include statements that are predictive in nature and depend upon or refer to future events or conditions, and include words such as “may,” “will,” “should,” “would,” “expect,” “anticipate,” “plan,” “likely,” “believe,” “estimate,” “project,” “intend,” “forecast,” “guidance”, “outlook” and other similar expressions among others. Forward-looking statements are based on current beliefs and assumptions that are subject to risks and uncertainties and are not guarantees of future performance. Actual results could differ materially from those contained in any forward-looking statement as a result of various factors, including, without limitation: the Company’s ability to protect its intellectual property rights; the Company’s anticipated capital requirements, including the Company’s anticipated cash runway and the Company’s current expectations regarding its plans for future equity financings; the Company’s dependence on additional financing to fund its operations and complete the development and commercialization of its product candidates, and the risks that raising such additional capital may restrict the Company’s operations or require the Company to relinquish rights to the Company’s technologies or product candidates; the Company’s limited operating history in the Company’s current line of business, which makes it difficult to evaluate the Company’s prospects, the Company’s business plan or the likelihood of the Company’s successful implementation of such business plan; the timing for the Company or its partners to initiate the planned clinical trials for Versamune® HPV, Infectimune®, PDS01ADC and other Versamune® based product candidates; the future success of such trials; the successful implementation of the Company’s research and development programs and collaborations, including any collaboration studies concerning Versamune® HPV, Infectimune®, PDS01ADC and other Versamune® based product candidates and the Company’s interpretation of the results and findings of such programs and collaborations and whether such results are sufficient to support the future success of the Company’s product candidates; the success, timing and cost of the Company’s ongoing clinical trials and anticipated clinical trials for the Company’s current product candidates, including statements regarding the timing of initiation, pace of enrollment and completion of the trials (including the Company’s ability to fully fund its disclosed clinical trials, which assumes no material changes to the Company’s currently projected expenses), futility analyses, presentations at conferences and data reported in an abstract, and receipt of interim or preliminary results (including, without limitation, any preclinical results or data), which are not necessarily indicative of the final results of the Company’s ongoing clinical trials; any Company statements about its understanding of product candidates mechanisms of action and interpretation of preclinical and early clinical results from its clinical development programs and any collaboration studies; the Company’s ability to continue as a going concern; and other factors, including legislative, regulatory, political and economic developments not within the Company’s control. The foregoing review of important factors that could cause actual events to differ from expectations should not be construed as exhaustive and should be read in conjunction with statements that are included herein and elsewhere, including the other risks, uncertainties, and other factors described under “Risk Factors,” “Management’s Discussion and Analysis of Financial Condition and Results of Operations” and elsewhere in the documents we file with the U.S. Securities and Exchange Commission. The forward-looking statements are made only as of the date of this press release and, except as required by applicable law, the Company undertakes no obligation to revise or update any forward-looking statement, or to make any other forward-looking statements, whether as a result of new information, future events or otherwise.  

Infectimune® and Versamune® are registered trademarks of PDS Biotechnology Corporation.

Investor Contact:

Mike Moyer
LifeSci Advisors
Phone +1 (617) 308-4306
Email: [email protected]

Media Contact:

Janine McCargo
6 Degrees
Phone +1 (646) 528-4034
Email: [email protected]



Posted on

Xunlei Limited Schedules 2025 Unaudited First Quarter Earnings Release on May 15, 2025

SHENZHEN, China, May 08, 2025 (GLOBE NEWSWIRE) — Xunlei Limited (“Xunlei” or the “Company”) (NASDAQ: XNET), a leading technology company providing distributed cloud services in China, today announced that it plans to release its unaudited financial results for the first quarter ended March 31, 2025 on May 15, 2025 before market open.

The earnings press release will be available on the Company’s investor relations page at http://ir.xunlei.com.

Conference Call

Xunlei’s management will host a conference call at 8:00 a.m. U.S. Eastern Time on May 15, 2025 (8:00 p.m. Beijing/Hong Kong Time), to discuss the Company’s quarterly results and recent business developments.

Conference Call Preregistration

Participant Online Registration:
https://register-conf.media-server.com/register/BIe31316b11951413ca6026dd0a7227b38

Please register to join the conference using the link provided above and dial in 10 minutes before the call is scheduled to begin. Once registered, the participants will receive an email with personal PIN and dial-in information, and participants can choose to access either via Dial-In or Call Me. A kindly reminder that “Call Me” does not work for China number.

The Company will also broadcast a live audio webcast of the conference call. The webcast will be available at http://ir.xunlei.com. Following the earnings conference call, an archive of the call will be available at https://edge.media-server.com/mmc/p/vrett8r2

About Xunlei

Founded in 2003, Xunlei Limited (NASDAQ: XNET) is a leading technology company providing distributed cloud services in China. Xunlei provides a wide range of products and services across cloud acceleration, shared cloud computing and digital entertainment to deliver an efficient, smart and safe internet experience.

Contact:

Xunlei Limited Investor Relations

Email: [email protected]
Tel: +86 755 6111 1571
Website: http://ir.xunlei.com



Posted on

Stryker declares an $0.84 per share quarterly dividend

Portage, Michigan, May 08, 2025 (GLOBE NEWSWIRE) — Stryker (NYSE:SYK) announced that its Board of Directors has declared a quarterly dividend of $0.84 per share payable July 31, 2025, to shareholders of record at the close of business on June 30, 2025, representing an increase of 5.0% versus the prior year and unchanged from the previous quarter. 

About Stryker

Stryker is a global leader in medical technologies and, together with our customers, we are driven to make healthcare better. We offer innovative products and services in MedSurg, Neurotechnology and Orthopaedics that help improve patient and healthcare outcomes. Alongside our customers around the world, we impact more than 150 million patients annually. More information is available at www.stryker.com.

Contacts

For investor inquiries:

Jason Beach, Vice President, Finance and Investor Relations at 269-385-2600 or [email protected] 

For media inquiries:

Kim Montagnino, Vice President, Chief Communications Officer at 269-385-2600 or [email protected]



Posted on

Merus to Present at BofA Securities 2025 Health Care Conference

UTRECHT, The Netherlands and CAMBRIDGE, Mass., May 08, 2025 (GLOBE NEWSWIRE) — Merus N.V. (Nasdaq: MRUS), an oncology company developing innovative, full-length multispecific antibodies (Biclonics® and Triclonics®), today announced that Bill Lundberg, M.D., President, Chief Executive Officer of Merus, will participate in a fireside chat at the BofA Securities 2025 Health Care Conference on Thursday, May 15, 2025 at 8:40 a.m. PT/11:40 a.m. ET.

The webcast of the presentation will be contemporaneously available on the Investors page of the Company’s website. The archived presentation will also be available there for a limited time after the event.


About Merus


Merus is an oncology company developing innovative full-length human bispecific and trispecific antibody therapeutics, referred to as Multiclonics®. Multiclonics® are manufactured using industry standard processes and have been observed in preclinical and clinical studies to have several of the same features of conventional human monoclonal antibodies, such as long half-life and low immunogenicity. For additional information, please visit Merus’ website and LinkedIn.

Multiclonics®, Biclonics® and Triclonics® are registered trademarks of Merus N.V.



Investor and Media Inquiries:
Sherri Spear
Merus N.V.
SVP Investor Relations and Strategic Communications
617-821-3246
[email protected]

Kathleen Farren
Merus N.V.
Director IR/Corp Comms
617-230-4165
[email protected]

Posted on

Operation HOPE Partners with Right Management to Provide Job Search Skills and Interview Preparation Services to HOPE Clients

Operation HOPE Partners with Right Management to Provide Job Search Skills and Interview Preparation Services to HOPE Clients

ATLANTA–(BUSINESS WIRE)–Operation HOPE, a national nonprofit dedicated to helping low and moderate-income Americans thrive in an ever-changing economy, today announced a three-year partnership with Talent Solutions Right Management, a global talent management provider of outplacement, coaching, and assessment solutions and part of the ManpowerGroup (NYSE: MAN), to provide Operation HOPE clients with resume writing guidance, interview preparation and job search skills at no cost. This partnership will further enhance Operation HOPE’s longstanding commitment to helping individuals take control of their financial futures by adding job search support to its existing coaching programs on credit and money management, small business development, homeownership, and more.

Right Management’s commitment to Operation HOPE and membership in “The 1865 Project,” an initiative aimed at growing and scaling the impactful work of Operation HOPE in communities across the U.S., will give HOPE clients access to programs ranging from application and resume development to job search skills and interview preparation. Right Management’s workshops will provide actionable resources and tools to support clients as they take the next step in owning their careers.

“We are thrilled to partner with Right Management, a world-class provider of career management solutions. At Operation HOPE, we have always been committed to providing the resources and tools necessary to help individuals from all backgrounds—particularly those from underserved communities—achieve financial stability and prosperity,” said John Hope Bryant, Founder, Chairman and CEO of Operation HOPE. “This partnership strengthens our mission by adding critical job search and interview preparation coaching to our suite of services. By empowering our clients with the expertise and support needed to navigate today’s job market, we are helping position them for the kind of success they have always dreamed of. Together with Right Management, we are helping to create lasting, positive change in the lives of those who need it most.”

“We are proud to partner with Operation HOPE, an organization that shares our dedication to empowering individuals and fostering economic stability,” said Karel van der Mandele, Senior Vice President for Right Management. “This collaboration is a testament to Right Management’s commitment to providing impactful career management solutions that can transform lives.”

Right Management, as a part of ManpowerGroup, believes that meaningful and sustainable employment has the power to change the world. Partnering with Operation Hope in this way aligns with the organization’s Ready for Work focus, centered around supporting individuals in developing work readiness skills.

“By integrating our expertise with Operation HOPE’s comprehensive financial coaching programs, we are creating a powerful synergy that will help individuals navigate the job market with confidence and achieve their career aspirations,” added Beth Linderbaum, Senior Vice President of Delivery. “Together, we are making a meaningful difference in communities across the nation, ensuring that everyone has the opportunity to thrive.”

About Operation HOPE, Inc.

Since 1992, Operation HOPE has been moving America from civil rights to “silver rights” with the mission of making free enterprise and capitalism work for the underserved—disrupting poverty for millions of low and moderate-income youth and adults across the nation. Through its community uplift model, HOPE Inside, which received the 2016 Innovator of the Year recognition by American Banker magazine, Operation HOPE has served more than 4 million individuals and directed more than $3.2 billion in economic activity into disenfranchised communities—turning check-cashing customers into banking customers, renters into homeowners, small business dreamers into small business owners, minimum wage workers into living wage consumers, and uncertain disaster victims into financially empowered disaster survivors. For more information: OperationHOPE.org. Follow the HOPE conversation on Twitter, Facebook, Instagram or LinkedIn.

About Talent Solutions Right Management

Talent Solutions combines our leading global offerings—RPO, TAPFIN-MSP and Right Management—to help organizations address their complex workforce needs. Talent Solutions leverages our deep industry expertise and understanding of what talent wants to provide end-to-end, data-driven capabilities across the talent lifecycle. Right Management is our global offering for outplacement, coaching, assessments, and career mobility. Right Management’s human touch, trusted expertise and scalable solutions power careers and propel organizations to new heights. For more information, visit right.com, or follow us on LinkedIn and Facebook.

Operation HOPE Contact:

Sarah Troutt, Mendel Communications

[email protected]

Right Management Contact:

Lisa Spathis

[email protected]

KEYWORDS: United States North America Georgia

INDUSTRY KEYWORDS: Human Resources Finance Professional Services Small Business Philanthropy Socially Responsible Investing Fund Raising Other Philanthropy Foundation

MEDIA:

Logo
Logo
Posted on

Bloom Energy Corporation Announces Exchange of a Portion of Its Existing 2.50% Green Convertible Senior Notes Due 2025 for 3.00% Green Convertible Senior Notes Due 2029

Bloom Energy Corporation Announces Exchange of a Portion of Its Existing 2.50% Green Convertible Senior Notes Due 2025 for 3.00% Green Convertible Senior Notes Due 2029

SAN JOSE, Calif.–(BUSINESS WIRE)–
Bloom Energy Corporation (NYSE: BE) today announced that on May 7, 2025, it entered into privately negotiated exchange agreements (the “Exchange Agreements”) with holders of its 2.50% green convertible senior notes due 2025 (the “2025 Convertible Notes”). Pursuant to the Exchange Agreements, Bloom Energy will exchange (the “Exchange Transaction”) approximately $112.8 million in aggregate principal amount of the 2025 Convertible Notes for approximately $115.7 million in aggregate principal amount of Bloom Energy’s 3.00% green convertible senior notes due 2029 (the “2029 Convertible Notes”). The Exchange Transaction is expected to settle on or about May 13, 2025, subject to customary closing conditions.

Upon completion of the Exchange Transaction, the aggregate principal amount of the 2025 Convertible Notes outstanding will be approximately $2.2 million, and the aggregate principal amount of the 2029 Convertible Notes outstanding will be approximately $518.2 million, which includes the 2029 Convertible Notes issued by Bloom Energy in May 2024. Bloom Energy will not receive any cash proceeds from the issuance of the 2029 Convertible Notes pursuant to the Exchange Transaction.

The 2029 Convertible Notes will be senior, unsecured obligations of Bloom Energy and will accrue interest at a rate of 3.00% per annum, payable semi-annually in arrears on June 1 and December 1 of each year. The 2029 Convertible Notes will mature on June 1, 2029, unless earlier repurchased, redeemed or converted. Before March 1, 2029, noteholders will have the right to convert their 2029 Convertible Notes only upon the occurrence of certain events. From and after March 1, 2029, noteholders may convert their 2029 Convertible Notes at any time at their election until the close of business on the second scheduled trading day immediately before the maturity date. Bloom Energy will settle conversions by paying or delivering, as applicable, cash, shares of its Class A common stock or a combination of cash and shares of its Class A common stock, at Bloom Energy’s election. The initial conversion rate is 47.9795 shares of Class A common stock per $1,000 principal amount of notes, which represents an initial conversion price of approximately $20.84 per share of Class A common stock. The conversion rate and conversion price will be subject to adjustment upon the occurrence of certain events. If a “make-whole fundamental change” (as defined in the indenture for the 2029 Convertible Notes) occurs, Bloom Energy will, in certain circumstances, increase the conversion rate for a specified time for holders who convert their 2029 Convertible Notes in connection with that make-whole fundamental change.

The 2029 Convertible Notes will be redeemable, in whole or in part (subject to certain limitations on partial redemptions), for cash at Bloom Energy’s option at any time, and from time to time, on or after June 7, 2027 and on or before the 21st scheduled trading day immediately before the maturity date, but only if the last reported sale price per share of Bloom Energy’s Class A common stock exceeds 130% of the conversion price for a specified period of time and certain other conditions are satisfied. The redemption price will be equal to the principal amount of the 2029 Convertible Notes to be redeemed, plus accrued and unpaid interest, if any, to, but excluding, the redemption date. If Bloom Energy calls any or all 2029 Convertible Notes for redemption, holders of 2029 Convertible Notes called for redemption may convert their 2029 Convertible Notes during the related redemption conversion period, and any such conversion will also constitute a “make-whole fundamental change” with respect to the notes so converted.

If a “fundamental change” (as defined in the indenture for the 2029 Convertible Notes) occurs, then, subject to a limited exception, noteholders may require Bloom Energy to repurchase their 2029 Convertible Notes for cash. The repurchase price will be equal to the principal amount of the 2029 Convertible Notes to be repurchased, plus accrued and unpaid interest, if any, to, but excluding, the applicable repurchase date.

The Exchange Transaction and any Class A common stock issuable upon conversion of the 2029 Convertible Notes have not been, and will not be, registered under the Securities Act of 1933, as amended (the “Securities Act”), or any other securities laws, and the 2029 Convertible Notes and any such Class A common stock cannot be offered or sold except pursuant to an exemption from, or in a transaction not subject to, the registration requirements of the Securities Act and any other applicable securities laws. This press release does not constitute an offer to sell, or the solicitation of an offer to buy, the 2025 Convertible Notes, the 2029 Convertible Notes or any Class A common stock issuable upon conversion of the 2029 Convertible Notes, nor will there be any sale of the 2029 Convertible Notes or any such Class A common stock, in any state or other jurisdiction in which such offer, sale or solicitation would be unlawful.

J. Wood Capital Advisors LLC acted as Bloom Energy’s financial advisor in connection with the Exchange Transaction.

Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking statements generally relate to future events or Bloom Energy’s future financial or operating performance. For example, statements regarding the completion of the Exchange Transaction are forward-looking statements. In some cases, you can identify forward-looking statements because they contain words such as “anticipate,” “believe,” “could,” “estimate,” “expect,” “intend,” “may,” “should,” “will” and “would” or the negative of these words or similar terms or expressions that concern Bloom Energy’s expectations, strategy, priorities, plans or intentions. However, not all forward-looking statements contain these identifying words. These statements may relate to market conditions, the satisfaction of the closing conditions related to the Exchange Transaction and risks relating to Bloom Energy’s business, that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the forward-looking statements. By their nature, these statements are subject to numerous uncertainties and risks, including factors beyond Bloom Energy’s control that could cause actual results, performance or achievement to differ materially and adversely from those anticipated or implied in the forward-looking statements. Other unknown or unpredictable factors also could have material adverse effects on Bloom Energy’s future results. More information on potential factors that may impact Bloom Energy’s business are set forth in Bloom Energy’s periodic reports filed with the SEC, including Bloom Energy’s Annual Report on Form 10-K for the year ended December 31, 2024, as filed with the SEC on February 27, 2025, and Bloom Energy’s Quarterly Report on Form 10-Q for the quarter ended March 31, 2025, as filed with the SEC on April 30, 2025, as well as subsequent reports filed with or furnished to the SEC from time to time. Bloom Energy assumes no obligation to, and does not currently intend to, update any such forward-looking statements.

Investor Relations:

Michael Tierney

Bloom Energy

[email protected]

Media:

Katja Gagen

[email protected]

KEYWORDS: United States North America California

INDUSTRY KEYWORDS: Alternative Energy Energy Utilities

MEDIA:

Logo
Logo
Posted on

Bradesco Stops Fraud with AI on FICO Platform, 1B Monthly Transactions, Double the Approval Speed

Bradesco Stops Fraud with AI on FICO Platform, 1B Monthly Transactions, Double the Approval Speed

Brazilian banking giant modernizes fraud detection and digital account opening, securing real-time transaction monitoring and seamless customer onboarding

HOLLYWOOD, Fla.–(BUSINESS WIRE)–FICO World 25 – FICO (NYSE: FICO)

Highlights:

  • Bradesco implemented FICO® Platform to modernize fraud detection and enhance digital account opening
  • The bank processes nearly 1 billion PIX transactions per month, reducing fraud-related customer friction by 89%
  • Transaction rejections have dropped by 25%, while real-time account openings have grown by 11%
  • Bradesco has won a 2025 FICO® Decision Industry Vanguard Award

At its FICO® World conference today, global analytics software leader FICO announced that Bradesco, one of Latin America’s largest banks, has overhauled its fraud prevention and digital banking systems using FICO® Platform. Serving more than 71 million customers, the bank now analyzes nearly 1 billion instant payments per month, reducing fraud-related disruptions while enabling real-time account openings. FICO Platform has strengthened security and improved the customer experience, making transactions efficient and account approvals seamless.

“Bradesco is more than a bank; we are a technology-driven financial institution that continuously evolves to meet customer needs,” said MarcosMolina, corporate security manager at Bradesco. “Since 2019, we have been building on FICO Platform, integrating AI-powered decisioning and digital onboarding. Now we have expanded this to fraud protection, boosting agility, security and efficiency with every innovation.”

Watch Bradesco tell their story on video: https://youtu.be/qivofgE35u8?si=jSS2-_l8l9g0nIz2

Securing Digital Transactions & Accelerating Account Openings

As Bradesco’s digital footprint expanded, transaction volumes surged. The bank needed to scale security without compromising the customer experience. Traditional fraud models struggled, frequently flagging legitimate transactions as suspicious. This forced customers to go through additional steps, such as calling the bank, verifying their identity, or confirming transactions manually—causing delays and frustration. Meanwhile, fraudsters adapted quickly, exploiting gaps in real-time monitoring.

To combat these challenges, Bradesco and FICO developed SAFER, an AI-powered fraud and compliance platform built on FICO Platform. SAFER processes up to 25 million PIX payments daily (Brazil’s instant payment system) enabling real-time transfers, detecting and preventing fraud in real time. By automating decisioning and reducing manual reviews, Bradesco cut the number of transactions held for further review by 89%, boosting both security and efficiency.

“The sheer volume of transactions we process daily meant we needed more than just stronger fraud detection — we needed a smarter, faster, and more scalable solution,” said Molina. “FICO helped us rethink our approach from the ground up, using AI and machine learning to stay ahead of fraudsters while ensuring a seamless experience for our customers. What we’ve built isn’t just a solution for today, but a foundation for the future of digital banking.”

Key achievements of Bradesco’s transformation include:

  • Fraud prevention at scale: Processes nearly 1 billion PIX transactions monthly, reducing fraud-related customer friction by 89% through fewer false positives, faster approvals, and less need for manual verification
  • Operational efficiency: Cut the number of transactions held for further review by 50%, enabling faster approvals
  • Real-time decisioning: Processes up to 25 million PIX payments per day, with a response time of just 50 milliseconds
  • Instant account opening: Reduced onboarding time from hours to real-time, increasing new accounts by 11%
  • Enhanced customer convenience: Reduced transaction rejections by 25% while maintaining strong fraud prevention

Bradesco is evolving into a fully digital, decision-driven institution. By expanding its use of FICO Platform, the bank is integrating AI-driven credit risk modeling and real-time transaction monitoring to enhance security, efficiency, and customer experience. SAFER remains central to this transformation, initially focusing on fighting fraud, monitoring digital transactions, and enabling real-time account openings through digital channels. Looking ahead, Bradesco envisions SAFER as a foundation for developing a comprehensive, 360º view of its customers, strengthening protection measures, and advancing Know Your Customer (KYC), anti-corruption, and anti-money laundering protocols.

“Processing nearly a billion transactions per month while reducing fraud-related friction is a remarkable feat,” said Nikhil Behl, president of software at FICO. “Bradesco’s transformation showcases how advanced decisioning and analytics on FICO Platform drive agility, efficiency and security at scale.”

For its achievements, Bradesco won a 2025 FICO® Decision Industry Vanguard Award.

To see the full list of 2025 FICO Decision Awards winners, check out: https://www.fico.com/en/decisionawards

About Bradesco

Bradesco is one of Brazil’s largest and most respected financial institutions, serving over 71 million customers. The bank is at the forefront of digital banking, utilizing cutting-edge technology to enhance customer experience and financial security. Bradesco is committed to financial inclusion, innovation, and sustainable development, ensuring seamless and secure banking for individuals and businesses across Brazil.

About the FICO® Decision Awards

The FICO Decisions Awards recognize organisations that are achieving remarkable success using FICO solutions. A panel of independent judges with deep industry expertise evaluates nominations based upon measurable improvement in key metrics; demonstrated use of best practices; project scale, depth and breadth; and innovative uses of technology. The 2025 judges are:

  • Regan Goble, risk analytics senior manager at Westpac NZ (Previous Winner)
  • Megha Kumar, research vice president at IDC
  • Joe McKendrick, analyst and senior contributor at Forbes
  • Luiz Pacete, technology and marketing industry influencer
  • Ali Paterson, founder and editor-in-chief at Fintech Finance
  • Mike Roberts, head of unsecured retail risk at HSBC UK bank (Previous Winner)
  • Erin Stillwell, EVP, payment partnerships at Blankfactor
  • Allan Tan, group editor-in-chief at Cxociety

The winners of the FICO Decisions Awards will be spotlighted at and win tickets to FICO® World 2025, May 6-9, 2025, at the Diplomat Hotel in Hollywood, Florida.

About FICO

FICO (NYSE: FICO) powers decisions that help people and businesses around the world prosper. Founded in 1956, the company is a pioneer in the use of predictive analytics and data science to improve operational decisions. FICO holds more than 200 US and foreign patents on technologies that increase profitability, customer satisfaction and growth for businesses in financial services, insurance, telecommunications, health care, retail and many other industries. Using FICO solutions, businesses in more than 80 countries do everything from protecting 4 billion payment cards from fraud, to improving financial inclusion, to increasing supply chain resiliency. The FICO® Score, used by 90% of top US lenders, is the standard measure of consumer credit risk in the US and has been made available in over 40 other countries, improving risk management, credit access and transparency.

Learn more at https://www.fico.com

Join the conversation at https://x.com/FICO_corp & https://www.fico.com/blogs/

For FICO news and media resources, visit https://www.fico.com/newsroom

FICO is a registered trademark of Fair Isaac Corporation in the U.S. and other countries.

InPress Porter Novelli

Cibely Toller

[email protected] / (11) 99858-8500

FICO

Thais Sabatini

[email protected]

KEYWORDS: Latin America North America United States Brazil South America Florida

INDUSTRY KEYWORDS: Banking Technology Professional Services Payments Electronic Commerce Security Data Analytics Software Artificial Intelligence Fintech Finance

MEDIA:

Logo
Logo
Posted on

Wells Fargo and Operation HOPE Introduce Free Financial Coaching to Small Businesses

Wells Fargo and Operation HOPE Introduce Free Financial Coaching to Small Businesses

New HOPE Inside centers expand financial education program in Wells Fargo branches

NEW YORK–(BUSINESS WIRE)–
Wells Fargo in collaboration with Operation HOPE, a national nonprofit dedicated to financial empowerment for underserved communities, today introduced HOPE Inside for Small Business to provide financial coaching and support to small business customers in key markets at no cost. Starting in Baldwin Hills and Van Nuys neighborhoods of Los Angeles, Calif., and Charlotte, N.C., this expansion builds on the existing HOPE Inside program that helps empower community members to achieve their financial goals through financial education workshops and personalized coaching.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250508538267/en/

Wells Fargo HOPE Inside for Small Business - three people walking past Wells Fargo branch (Credit: Wells Fargo)

Wells Fargo HOPE Inside for Small Business – three people walking past Wells Fargo branch (Credit: Wells Fargo)

Wells Fargo first launched HOPE Inside centers in 2022 to serve individuals with their personal finances and help build financial resilience through guidance in areas like budgeting, credit building, and money management. The new Small Business HOPE Inside centers will now offer those same specialized resources for small business owners in addition to business plan development, access to capital education and more. Through one-on-one coaching, entrepreneurs will receive personalized support to help start, grow, and sustain their businesses.

“We know that having access to trusted financial guidance is invaluable,” said April Schneider, head of Small and Business Banking at Wells Fargo. “This kind of continued community investment showcases how important small businesses are to our communities and our commitment to help them thrive.”

HOPE Inside centers are located inside Wells Fargo branches in select markets, and feature Operation HOPE financial coaches who foster financial inclusion and economic empowerment. The branches feature redesigned and updated spaces created to deliver one-on-one consultations, improve digital access, and offer financial health workshops.

“Small businesses are the backbone of our communities, and we want to provide them with the tools and resources they need to succeed,” said Michael Martino, head of Banking Inclusion Initiative at Wells Fargo. “Expanding HOPE Inside to support small businesses is a natural evolution of our work with Operation HOPE and reinforces our shared vision of building stronger, more financially resilient communities.”

“Strategic partnerships are the backbone of community transformation and Wells Fargo has been with us since the beginning. We are deeply grateful for their commitment to increasing economic inclusion by expanding our HOPE Inside for Small Business footprint,” said John Hope Bryant, founder, Chairman and CEO, Operation HOPE. “This collaboration empowers aspiring entrepreneurs and small business owners with financial coaching and education — meeting them where they are and helping them build a future rooted in financial confidence and success.”

The expansion is part of a broader national effort through Wells Fargo’s Banking Inclusion Initiative to bring HOPE Inside to 50 markets across the U.S. by 2026. Currently at 30 HOPE Inside centers, serving over 100 branches, the impact of the program has helped more than eleven thousand clients since launching in 2022. All services offered through HOPE Inside are at no cost and available to community members, whether they are Wells Fargo customers or not.

Wells Fargo’s Banking Inclusion Initiative was started in 2021 to help more people who are unbanked gain access to affordable, mainstream banking products, and financial education.

About Wells Fargo

Wells Fargo & Company (NYSE: WFC) is a leading financial services company that has approximately $1.9 trillion in assets. We provide a diversified set of banking, investment and mortgage products and services, as well as consumer and commercial finance, through our four reportable operating segments: Consumer Banking and Lending, Commercial Banking, Corporate and Investment Banking, and Wealth & Investment Management. Wells Fargo ranked No. 34 on Fortune’s 2024 rankings of America’s largest corporations. News, insights, and perspectives from Wells Fargo are also available at Wells Fargo Stories.

Additional information may be found at www.wellsfargo.com.

LinkedIn: https://www.linkedin.com/company/wellsfargo

WF-BL

Media

Aryel Bell, 704-787-3420

[email protected]

KEYWORDS: United States North America New York

INDUSTRY KEYWORDS: Entrepreneur Finance Consulting Banking Business Professional Services Hispanic Small Business Consumer

MEDIA:

Photo
Photo
Wells Fargo HOPE Inside for Small Business – three people walking past Wells Fargo branch (Credit: Wells Fargo)
Posted on

Rahway Public Schools Deploys Evolv Technology to Enhance Student Safety

Rahway Public Schools Deploys Evolv Technology to Enhance Student Safety

Rahway Public Schools adopts Evolv Express® and Evolv eXpedite™ to strengthen entryway safety

WALTHAM, Mass.–(BUSINESS WIRE)–
Evolv Technologies Holdings, Inc. (NASDAQ: EVLV), a leading security technology company pioneering AI-based solutions designed to create safer experiences, today announced its partnership with Rahway Public Schools in Rahway, NJ. The district recently installed Evolv Express® and Evolv eXpedite™ systems at its gymnasium and performing arts entrances, marking a significant step forward in school security. The combination of Express and eXpedite will allow students to be screened without having to take laptops out of their bags.

“Our top priority is the safety and well-being of our staff, students, and families,” said Dr. Shoieb, Superintendent of Rahway Public Schools. “With Evolv, we are able to screen students efficiently without compromising their sense of security or disrupting their day. We’re proud to be the first school district in New Jersey to implement the eXpedite solution in combination with Express to help detect threats without putting an excess burden on our staff.”

“This partnership reflects Rahway’s proactive commitment to student safety,” said Dean Marcantonio, Director of Safety and Security for Rahway Public Schools. “The integration of Evolv’s systems is a game-changer for how we think about securing our schools.”

“We are honored to support Rahway Public Schools in their commitment to student safety,” said John Kedzierski, President and Chief Executive Officer of Evolv Technology. “Since Evolv eXpedite’s launch in September 2024, we have seen momentum among customers who have begun to add the system into their layered safety plan. Rahway is setting the standard for how schools can use innovative technology to provide an efficient and welcoming environment for learning.”

With this deployment, Rahway Public Schools joins over 1,100 school buildings nationwide that are turning to Evolv’s advanced security technology to help enhance safety while maintaining welcoming learning environments. Evolv remains committed to helping educational institutions protect their communities with solutions that are fast, intelligent, and efficient.

About Evolv Technology

Evolv Technologies Holdings, Inc (NASDAQ: EVLV) is designed to transform human security to make a safer, faster, and better experience for the world’s most iconic venues and companies as well as schools, hospitals, and public spaces, using industry leading artificial intelligence (AI)-powered screening and analytics. Its mission is to transform security to create a safer world to live, work, learn, and play. Evolv has digitally transformed the gateways in many places where people gather by enabling seamless integration combined with powerful analytics and insights. Evolv’s advanced systems have scanned more than two billion people since 2019. Evolv has been awarded the U.S. Department of Homeland Security (DHS) SAFETY Act Designation as a Qualified Anti-Terrorism Technology (QATT) as well as the Security Industry Association (SIA) 2024 New Products and Solutions (NPS) Award in the Law Enforcement/Public Safety/Guarding Systems category, as well as Sport Business Journal’s (SBJ) 2024 awards for “Best In Fan Experience Technology” and “Best In Sports Technology”. Evolv®, Evolv Express®, Evolv Insights®, Evolv Visual Gun Detection™, Evolv eXpedite™, and Evolv Eva™ are registered trademarks or trademarks of Evolv Technologies, Inc. in the United States and other jurisdictions. For more information, visit evolv.com.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Evolv Technology intends such forward-looking statements to be covered by the safe harbor provisions for forward-looking statements contained in Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All statements other than statements of historical fact are statements that could be deemed forward-looking statements, including statements made in the quotes from executives and directors and statements regarding the Company’s execution of its strategy, financial and operational performance and growth and creating value for stakeholders. Forward-looking statements involve known and unknown risks, uncertainties and other important factors that may cause our actual results and actions to be materially different from any future results or actions expressed or implied by the forward-looking statements, including, but not limited to, the factors discussed under the caption “Risk Factors” in our Annual Report on Form 10-K for the year ended December 31, 2024 filed with the Securities and Exchange Commission (“SEC”) on April 28, 2025 as any such factors may be updated from time to time in our other filings with the SEC, could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. . The forward-looking statements in this press release are based upon information available to us as of the date hereof, and while we believe such information forms a reasonable basis for such statements, it may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and investors are cautioned not to unduly rely upon these statements.

Except as required by applicable law, we do not plan to publicly update or revise any forward-looking statements contained in this press release, whether as a result of any new information, future events or otherwise.

Investor Relations:

Brian Norris

[email protected]

Media Relations:

Alexandra Smith Ozerkis

[email protected]

KEYWORDS: United States North America Massachusetts New Jersey

INDUSTRY KEYWORDS: Primary/Secondary Education Security Technology Other Education Artificial Intelligence

MEDIA:

Logo
Logo